CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) - EUR (€) € in Thousands, shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue
Research and Development	€ 0	€ 0	€ 3	€ 0
Grants	34	130	411	909
Revenues	34	130	414	909
Expenses
Research and development	60	209	854	1,191
General and administrative	355	320	1,515	979
Total expenses	415	529	2,369	2,170
Operating Loss	(381)	(399)	(1,955)	(1,261)
Interest expense	710	703	2,118	2,096
Goodwill impairment	0	0	6,671	0
Other (income) expense	23	243	84	541
Loss before income tax provision	(1,114)	(1,345)	(10,660)	(3,898)
Income tax provision	0	0	0	0
Net Loss	(1,114)	(1,345)	(10,660)	(3,898)
Other comprehensive income
Foreign currency translation adjustment	(5)	(7)	(14)	(2)
Comprehensive loss	€ (1,119)	€ (1,352)	€ (10,674)	€ (3,900)
Basic and dilutive earnings per share	€ (0.00)	€ (0.00)	€ (0.04)	€ (0.01)
Weighted-average shares outstanding, basic and diluted	303,757,622	303,757,622	303,757,622	303,757,622